Waiting can make a lot sense for the wealthy, although there is one risk to consider.
This company's hemp-derived CBD products will soon be carried by the nation's largest grocery retailer.
Here's when the risk-versus-reward profile for the most popular pot stock in the world would favor long-term investors.
Despite losing two-thirds of its value since September, 15% additional downside could await this NYSE-listed cannabis stock.
The answer may surprise you.
These household names are hoping the green rush boosts their bottom lines.
Pessimism may be waning for these three popular cannabis stocks.
This research deal is far more valuable than investors may realize.
Embattled pot stock CannTrust took its most logical first step forward. Here's what could happen next.
This is one of many smoking-hot deals and partnerships in the cannabis space.
This undiscovered pot stock has all the tools needed to succeed.
The U.S. Food and Drug Administration's harsh stance on cannabidiol should surprise no one.
Investing in marijuana stocks isn't as cut-and-dried as you might think.
These time-tested businesses are very close to joining an elite group of income stocks.
These are the only cannabis stocks with a billion-dollar valuation.
These adjustments could directly impact the wallets of program beneficiaries -- and even nonretirees -- next year.
Are these historically anti-cannabis states turning over a new leaf?
Despite mirroring the federal tax schedule on Social Security benefits as recently as 2016, these four states have made strides to become tax-friendly.
Despite being an industry leader, Canopy Growth's valuation should make investors cringe.
Growing federal debt obligations aren't a big deal for the most successful social program in history.